canSERV Releases Open Call for Transnational Service Provision
One document
more
Stories about Krebs
Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots/PRNewswire) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic ...
moreHearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ...
more- 4
PIONEER Big Data in Prostate Cancer Platform Opens up to Asian Data Sets
more Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration
Aachen, Germany and Tokyo, Japan (ots) - - The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines - The new enterprise will be branded as Grünenthal Meds. Grünenthal owns a 51 percent majority share and ...
moreWildDISCO: Visualizing Whole Bodies in Unprecedented Detail
more
Potentiating Cancer Vulnerability to Ferroptosis: Off-Targeting Effects of DHODH Inhibitors
more- 2
CARAMBA: New Hope for Multiple Myeloma Patients
more New Approach in Cancer Therapy With Innovative Mechanism-of-Action for Ferroptosis Induction
moreRHEACELL announces “First Patient In”: EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected
moreFirst Integrated Single-Cell Atlas of the Human Lung
Can a human organ be mapped on a single-cell level to learn about the functionality of each individual cell? And can we learn how different these cells are from person to person? Helmholtz Munich researchers and their collaborators have taken up this challenge and developed the Human Lung Cell Atlas using artificial intelligence (AI)-based techniques. This atlas elucidates the diversity of single lung cell types and ...
moreThe Medias Hospital is Raising the Bar for Interventional Oncology as an IASIOS Enrolled Centre
Burghausen/Germany (ots) - The Medias Hospital has officially enrolled in the accreditation program of IASIOS to further ensure highest quality standards in Interventional Oncology as an important aspect of oncological patient care. The Medias Hospital has taken the next step to committing to the highest standards when it comes to interventional oncology (IO) care and ...
more
DEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER WITH WEE1 INHIBITOR DEBIO 0123 TO OUTSMART DDR IN SMALL CELL LUNG CANCER
Lausanne, Switzerland (ots) - - Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC). - The first patient dosed at Vall d’Hebron Hospital (Barcelona, Spain), was ...
moreDEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS
Lausanne (ots) - - Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. - Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage ...
moreThe world's first Extended Isolated Stopflow Limb Infusion (EISLI) to treat osteosarcoma results in complete remission
moreIEVA (Independent European Vape Alliance)
World Cancer Day - Decrease smoking rates with reduced-risk alternatives
Brussels (ots) - 19.7 percent of the EU population are daily smokers. [1] 700,000 people in the EU die each year as a result of smoking and every second smoker dies on average 14 years prematurely. [2] Smoking is the leading cause of preventable cancer, with 27 percent of all cancers attributed to tobacco. [3] The examples of Great Britain (smoking rate: 13.8 percent) ...
moreTechnische Universität München
New X-ray technology can improve Covid-19 diagnosis
TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de Images: https://mediatum.ub.tum.de/1692790 NEWS RELEASE New X-ray technology can improve Covid-19 diagnosis Patient study demonstrates benefits of dark-field X-ray technology A research team at the Technical University of Munich (TUM) has, for the first time, produced dark-field X-ray images of ...
moreTechnische Universität München
Nanoswitches for tumor targeting
TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de Video: https://www.youtube.com/watch?v=_xXV0mCke1g NEWS RELEASE Nanoswitches for tumor targeting TUM spin-off Plectonic develops antibody-based immunotherapies Plectonic Biotech, a spin-off of the Technical University of Munich (TUM), has developed a nanoswitch that binds immune cells to tumor cells. The goal is to facilitate the development of ...
more
Klinik für Prostata-Therapie Heidelberg
Focal therapy for prostate cancer: Reliable diagnosis leads to gentle treatment
moreTechnische Universität München
Improved monitoring of silicone implants
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10808 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/aktuelles/alle-meldungen/pressemitteilungen/details/verbessertes-monitoring-von-silikonimplantaten Pictures: https://mediatum.ub.tum.de/1687409 NEWS RELEASE Improved monitoring of silicone implants New algorithm for clinical MRI scanners makes breast ...
moreEuropean Society for Medical Oncology (ESMO)
ESMO 2022 - Great oaks grow from small acorns: oncology is committed to doing its part for sustainability
Paris (ots) - At ESMO 2022, 9-13 September, Paris, France, the premier cancer congress in Europe, which has gathered 28k participants from 167 countries, many discussions will be around sustainability, prevention and novel approaches which could soon become a reality in the clinic. - Late-breaking results elucidate ...
moreEuropean Inventor Award 2022: Meet the inventors that are shaping our world at virtual event
Munich (ots) - - The winners of the European Patent Office’s annual innovation prize will be revealed at a ceremony on 21 June 2022 at 12:00 CEST held in an all-new format - Discover the stories of 14 exceptional inventor teams and 4 young innovators from 14 countries - The public is now invited to vote for their favourite inventor to win the Popular Prize at ...
moreIs microplastic carcinogenic?
Graz/Vienna (ots) - The effects of micro- and nanoplastic particles (MNP) in the human body are being investigated in depth for the first time worldwide. From 2022 to 2025, research will be performed at CBmed together with international partners to elucidate potential health effects of microplastics. Every person in developed countries currently ingests an average of five grams of plastics per week - that's as much as a standard credit card. What these micro- and nanoplastic ...
moreTechnische Universität München
Overcoming resistance of pancreatic cancer to immunotherapies
Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37173 High resolution images: https://mediatum.ub.tum.de/1641984 NEWS RELEASE “Inflaming” cold tumors Overcoming resistance of pancreatic cancer to immunotherapies Pancreatic carcinoma is a ...
more
University of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA from Blood of Neck and Throat Cancer Patients
Baltimore, MD (ots) - Sysmex Inostics, a global leader in the liquid biopsy revolution for oncology, announces the use of their HPV-SEQ test in the prospective University of Chicago clinical trial,1 “Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer.” “The ability to reliably detect HPV-DNA ...
moreIEVA (Independent European Vape Alliance)
Vaping industry underlines the importance of product choice
Brussels (ots) - The Independent European Vape Alliance (IEVA) welcomed the decision of MEPs to recognize tobacco harm reduction as a tool in beating cancer; but remains concerned that the report approved today by the European Parliament leaves the door open to a flavour ban in the EU. The Special Committee on Beating Cancer (BECA) today voted on the amendments and the draft of the Beating Cancer report by Rapporteur ...
moreCHRISTMAS COMES EARLY FOR CHILDREN WITH CANCER COURTESY OF PM-INTERNATIONAL MALAYSIA
moreTechnische Universität München
New X-ray technology: Dark-field X-ray technology improves diagnosis of pulmonary ailments
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/36892 High resolution images: https://mediatum.ub.tum.de/1621886 NEWS RELEASE New X-ray technology first used with patients Dark-field X-ray technology ...
moreNew Ultra-Sensitive Leukemia Blood Test Delivered by Sysmex Inostics
moreTechnische Universität München
A protein causes higher risk of severe cancer progression for men
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/36939 High resolution images: https://mediatum.ub.tum.de/1631416 NEWS RELEASE Cause found for higher sex-specific risk of mortality A protein causes significantly higher risk of severe cancer progression for men A ...
more
Previous1234Next